Study finds that higher copays promote more drug noncompliance
A new study funded by GlaxoSmithKline found that Type 2 diabetics who have to shell out higher copays are more likely to not take their drugs as indicated.
A new study, published in the Journal of Occupational and Environmental Medicine, has reinforced what pharmacists have known all along-that higher co-payments lead to lower drug compliance and higher healthcare costs. The study involved looking at the medical and pharmacy claims for PPG Industries’ 2,052 employees, dependents, and retirees with Type 2 diabetes over a two-year period. The study found that those with lower co-payments adhered better to their oral diabetes medicines and averaged $3,116 less per year in total healthcare costs than those in the highest ($20+) co-payment group. PPG Industries is a global manufacturer of coatings, glass, and chemical products. The study was funded by GlaxoSmithKline.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Psychiatric Pharmacist Working to Optimize Treatment, Improve Patient Safety
December 13th 2024A conversation with Nina Vadiei, PharmD, BCPP, clinical associate professor in the Division of Pharmacotherapy at University of Texas at Austin College of Pharmacy and a clinical pharmacy specialist in psychiatry at the San Antonio State Hospital.
